Scaling Up Community-based Noncommunicable Disease Research Into Practice in Pokhara Metropolitan City of Nepal
Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Dec 13, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping people in Pokhara, Nepal, who have high blood pressure, type 2 diabetes, or who smoke cigarettes. The researchers want to see if a program that includes home visits by trained female community health volunteers and regular text messages can improve health outcomes. Specifically, they are looking to find out if these visits and messages can lower blood pressure, reduce blood sugar levels, and help smokers quit.
To participate in this study, individuals must be at least 18 years old, live in Pokhara, and meet at least one of the following criteria: they have high blood pressure, type 2 diabetes, or they smoke. Participants will be compared to a group that does not receive these additional services. If you join the study, you can expect support from health volunteers who will help you manage your condition through personalized advice and regular check-ins via text messages. This trial is not yet recruiting participants, but it aims to make a positive impact on community health in Pokhara.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Meeting at least one of the following three conditions
- • Hypertensive, as defined as
- • BP≥140/90 mmHg at two separate measurements, or
- • Under pharmacotherapies for hypertension
- • Type 2 diabetes, as defined as
- • Fingerprick glucose≥100 mg/dL, and plasma fasting glucose ≥126 mg/dL, and HbA1c≥6.5, or
- • Under pharmacotherapies for type 2 diabetes
- • Current smoker, as defined as
- • Ever smoked ≥100 cigarettes in lifetime, and
- • Currently smokes every day or on some days.
- • 2. Registered on the voter list in Pokhara.
- • 3. Not plan to migrate outside of Pokhara during the study period
- Exclusion Criteria:
- • 1. Blood pressure ≥180/120 mmHg or
- • 2. Blood glucose \>250 mg/dL or \<54 mg/dL
- • 3. Diagnosed with secondary hypertension by health professionals
- • 4. Diagnosed with other diabetes besides type 2 by health professionals
- 5. Presenting with acute symptoms that may require hospitalizations, which includes but not limited to:
- • Nausea, vomiting, diarrhea
- • Abdominal pain
- • Polyuria, polydipsia, polyphagia
- • Loss of motor or sensory function
- • Altered mental status.
- • Chest pain, chest tightness
- • Dyspnea, shortness of breath
- • Fever
- • 6. Diagnosed as terminally ill by a health professional, defined as life expectancy of 6 months or less.
- • 7. Pregnant or intend to be pregnant
About Johns Hopkins Bloomberg School Of Public Health
The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pokhara, Gandaki, Nepal
Patients applied
Trial Officials
Dinesh Neupane, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported